Table 3. Occurrence of cancer in people who had undergone knee replacement at least a year before: number of people in the reference cohorta with each cancer, observed and expected number of people with cancer in the knee replacement cohort, ratio of rates in the knee replacement cohort to that in the reference cohort, and 95% confidence intervals for the rate ratio.
| Cancer (ICD code)b | Number in cohort | Person-years of follow-upc | Observed number in knee replacement | Expected number in knee replacement | Adjusted rate ratiod | 95% confidence interval |
|---|---|---|---|---|---|---|
| All cancers (140–208) | 24 691 | 5 586 906 | 640 | 609 | 1.05 | 0.97–1.14 |
| Upper gastrointestinal (140–141, 143–146, 148–149,) | 373 | 5 695 396 | 8 | 9.9 | 0.81 | 0.35–1.61 |
| Salivary gland (142) | 98 | 5 696 463 | 0 | 1.7 | 0.00 | 0–2.17 |
| Nasopharynx (147) | 47 | 5 697 482 | 0 | 0.7 | 0.00 | 0–5.27 |
| Oesophagus (150) | 860 | 5 696 753 | 26 | 22.6 | 1.15 | 0.75–1.74 |
| Stomach (151) | 1480 | 5 695 381 | 23 | 31.7 | 0.73 | 0.46–1.09 |
| Colon (153) | 1751 | 4 548 060 | 60 | 67.7 | 0.89 | 0.67–1.14 |
| Rectum (154) | 1010 | 4 550 822 | 46 | 35.0 | 1.31 | 0.96–1.75 |
| Liver (155) | 316 | 5 697 605 | 14 | 8.6 | 1.63 | 0.89–2.73 |
| Pancreas (157) | 889 | 5 697 157 | 42 | 23.9 | 1.76 | 1.27–2.38 |
| Lung (162) | 4309 | 5 693 572 | 88 | 96.3 | 0.91 | 0.73–1.13 |
| Breast (174, 175) | 2375 | 5 679 995 | 84 | 79 | 1.06 | 0.85–1.32 |
| Cervix (180) | 216 | 2 284 790 | 3 | 5.6 | 0.54 | 0.11–1.57 |
| Uterus (182) | 373 | 2 284 294 | 15 | 14 | 1.07 | 0.60–1.77 |
| Ovary (183.0) | 137 | 2 287 535 | 10 | 7.3 | 1.37 | 0.66–2.52 |
| Prostate (185) | 2426 | 3 402 004 | 48 | 48.8 | 0.98 | 0.73–1.30 |
| Testis (186) | 142 | 3 408 318 | 0 | 0.5 | 0.00 | 0–7.38 |
| Kidney (189.0, 189.1) | 515 | 5 695 635 | 8 | 10.5 | 0.76 | 0.33–1.50 |
| Bladder (188) | 1756 | 5 686 618 | 46 | 40.4 | 1.14 | 0.83–1.52 |
| Malignant melanoma (172) | 399 | 5 695 011 | 6 | 8.6 | 0.70 | 0.26–1.52 |
| Other skin cancer (173) | 1949 | 5 681 235 | 72 | 53.4 | 1.35 | 1.05–1.70 |
| Brain (malignant) (191) | 447 | 5 696 603 | 8 | 8 | 1.00 | 0.43–1.97 |
| Other nervous system (192) | 56 | 5 697 390 | 0 | 0.8 | 0.00 | 0–4.61 |
| Thyroid (193) | 111 | 5 696 325 | 2 | 1.3 | 1.54 | 0.19–5.56 |
| Bone (170) | 162 | 5 696 908 | 2 | 3.6 | 0.56 | 0.07–2.01 |
| Lymphoma (200–202) | 932 | 5 692 728 | 27 | 20.2 | 1.34 | 0.88–1.94 |
| Non-Hodgkin's lymphoma (200, 202) | 824 | 5 694 332 | 24 | 19.8 | 1.21 | 0.78–1.80 |
| Hodgkin's disease (201) | 163 | 5 695 843 | 3 | 1.4 | 2.14 | 0.44–6.26 |
| Multiple myeloma (203) | 463 | 5 696 638 | 15 | 12.9 | 1.16 | 0.65–1.92 |
| Leukaemia (204–208) | 820 | 5 695 219 | 16 | 19.7 | 0.81 | 0.46–1.32 |
| Lymphoid leukaemia (204) | 393 | 5 696 069 | 7 | 9.3 | 0.75 | 0.30–1.55 |
| Myeloid leukaemia (205) | 420 | 5 697 041 | 10 | 10 | 1.00 | 0.48–1.84 |
| Brain (benign) (225) | 252 | 5 693 620 | 2 | 4.4 | 0.45 | 0.06–1.64 |
For reference conditions and methods of standardisation, see footnotes of Table 2.